Page last updated: 2024-12-05

indapamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indapamide is a thiazide-like diuretic medication used to treat high blood pressure. It is synthesized through a multi-step process involving the reaction of 4-chloro-3-sulfamoylbenzoic acid with 2-amino-4-methylthiazole. Indapamide acts by inhibiting the reabsorption of sodium and chloride ions in the distal tubules of the kidneys, leading to increased urine output and a reduction in blood pressure. This effect is achieved by blocking the sodium-chloride symporter (NCC). Indapamide is also known to have a vasodilatory effect on blood vessels, further contributing to its antihypertensive action. It is studied extensively for its effectiveness in managing hypertension and its potential benefits in other conditions, such as heart failure and metabolic syndrome. The medication is generally well-tolerated, although some individuals may experience side effects like headache, dizziness, and muscle cramps.'

Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Natrixgenus[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID3702
CHEMBL ID406
CHEBI ID5893
SCHEMBL ID41303
MeSH IDM0011207

Synonyms (187)

Synonym
MLS001148152
AB00052021-15
AB00052021-14
BRD-A95869247-001-04-6
DIVK1C_000508
KBIO1_000508
SPECTRUM_000917
BPBIO1_000263
PRESTWICK3_000220
natrilix
cormil
lozol
tertensif
brn 1604026
ipamix
4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide
benzamide, 3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-l-yl)-
s-1520 ,
se 1520
damide
fludex
benzamide, 3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)-
bajaten
indaflex
benzamide, 4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoyl-
noranat
indamol
indapamidum [inn-latin]
se-1520
3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)benzamide
usv 2555
indapamida [inn-spanish]
einecs 248-012-7
tandix
arifon
pressurai
rhc 2555
26807-65-8
indapamide
SPECTRUM5_000866
veroxil
BSPBIO_000239
bdbm25901
4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)-3-sulfamoylbenzamide
AB00052021
metindamide
DB00808
lozol (tn)
natrix (tn)
indapamide (jp17/usp)
D00345
NCGC00089727-02
NCGC00089727-03
smr000058829
MLS000028554 ,
KBIOGR_000393
KBIO2_003965
KBIO3_001394
KBIOSS_001397
KBIO2_006533
KBIO2_001397
NINDS_000508
SPBIO_001019
SPECTRUM2_000980
SPECTRUM4_000017
SPECTRUM3_000467
SPECTRUM1500349
IDI1_000508
BSPBIO_002174
HMS2090M16
AC-2073
HMS2091N07
I0730
1-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline
MLS002222229
chebi:5893 ,
natrix
flupamid
CHEMBL406
kyd-041
nsc-757075
fludin
flubest
indamide
lorvas
HMS501J10
HMS1920F19
4-chloro-n-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
A23574
NCGC00018172-04
NCGC00018172-03
NCGC00018172-06
NCGC00018172-02
HMS3259C14
HMS2095L21
S1520 ,
dtxcid5024633
dtxsid7044633 ,
NCGC00256884-01
tox21_302687
tox21_113182
pharmakon1600-01500349
nsc757075
tox21_110775
STL257105
HMS2231G13
CCG-40198
nsc 757075
f089i0511l ,
indapamida
indapamide [usan:usp:inn:ban:jan]
indapamidum
5-20-06-00348 (beilstein handbook reference)
unii-f089i0511l
NCGC00018172-08
AB03037
S1730
AKOS015888148
gtpl7203
HMS3369J20
hypen sr
STL455045
4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)-3-sulfamoylbenzenecarboximidic acid
indapamide [ep impurity]
indapamide [mi]
indapamide [vandf]
indapamide [orange book]
indapamide [ep monograph]
indapamide [usp-rs]
indapamide [usan]
indapamide [mart.]
indapamide [inn]
indapamide [jan]
indapamide [who-dd]
indapamide [usp monograph]
HY-B0259
NC00568
3-(aminosulphonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)benzamide
4-chloro-3-aminosulphonyl-n-(2,3-dihydro2-methyl-1h-indol-1-yl)benzamide
3-(aminosulphonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1--yl)benzamide
3-aminosulfonyl-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)benzamide
SCHEMBL41303
NCGC00018172-09
tox21_110775_1
KS-5219
3-(aminosulfonyl)-4-chloro-n-(2-methyl-2,3-dihydro-1h-indol-1-yl)benzamide
MLS006011900
n-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline
4-chloro-n-(2-methylindolin-1-yl)-3-sulfamoylbenzamide
OPERA_ID_110
AB00052021_17
AB00052021_16
mfcd00079375
SR-01000003079-2
sr-01000003079
indapamide, united states pharmacopeia (usp) reference standard
indapamide, european pharmacopoeia (ep) reference standard
indapamide, analytical standard, for drug analysis
HMS3655E06
indapamide, pharmaceutical secondary standard; certified reference material
indapamide 1.0 mg/ml in methanol
SR-01000003079-3
J-016554
SBI-0051415.P003
HMS3712L21
indapamide, british pharmacopoeia (bp) reference standard
SW198686-2
BCP04140
Z1501485351
indapamide (lozol)
Q1078392
BRD-A95869247-001-14-5
26807-65-8(free base)
AMY31945
HMS3748K05
EN300-117260
indapamide (usp monograph)
indapamide (ep impurity)
indapamide (usan:usp:inn:ban:jan)
indapamid
4-chloro-n-((2rs)-2-methyl-2,3-dihydro-1h-indol-1-yl)-3-sulfamoylbenzamide
indapamide (mart.)
c03ba11
indapamide (ep monograph)
indapamide (usp-rs)
indapamidum (inn-latin)
indapamida (inn-spanish)

Research Excerpts

Overview

Indapamide is a sulfonamide diuretic with vasodilative and calcium antagonistic effects. It enhances sodium delivery to the renal distal tubules resulting in a dose-related increase in urinary potassium excretion and decreases serum potassium concentrations.

ExcerptReferenceRelevance
"Indapamide is an orally administered diuretic antihypertensive drug."( Assessment of the genotoxic effects of antihypertensive drug active ingredient indapamide in human lymphocytes.
Avuloglu-Yilmaz, E; Unal, F; Yuzbasioglu, D, 2023
)
1.86
"Indapamide is a sulfonamide diuretic with vasodilative and calcium antagonistic effects, which enhances sodium delivery to the renal distal tubules resulting in a dose-related increase in urinary potassium excretion and decreases serum potassium concentrations."( [Intraoperative management of potentially fatal arrhythmias after anesthesia induced by severe hypokalemia: A case report].
Guo, XY; Wang, JC; Yao, YX, 2023
)
1.63
"Indapamide is an antihypertensive agent similar to thiazides, but with some different effects. "( Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease.
Algun, E; Can, S; Ceylan, K; Dogan, E; Erkoc, R; Gonulalan, H; Sayarlioglu, H; Topal, C; Yilmaz, Y, 2005
)
2.17
"Indapamide is a well known blocker of the slow component of the delayed rectifier current leading to prolongation of cardiac repolarization."( QT interval prolongation and torsade de pointes associated with indapamide.
Alexanian, IP; Efremidis, M; Kardaras, F; Kounas, SP; Letsas, KP; Pappas, LK; Sideris, A, 2006
)
1.29
"Indapamide is a useful antihypertensive agent with good patient tolerance in mild or moderate hypertension and may offer advantages over traditional diuretics in view of its possible vasodilator and calcium-antagonist properties, once-a-day dosage, and good therapeutic effect with prolonged usage."( Clinical efficacy and safety of indapamide in essential hypertension.
Morledge, JH, 1983
)
1.27
"Indapamide is an orally active sulphonamide diuretic agent. "( Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.
Avery, GS; Brogden, RN; Chaffman, M; Heel, RC; Speight, TM, 1984
)
3.15
"Indapamide (Lozol) is a new diuretic and antihypertensive agent. "( Indapamide: a unique diuretic?
Conner, CS, 1983
)
3.15
"Indapamide is a new indoline antihypertensive diuretic agent whose chemical structure differs substantially from those of the thiazides. "( Preclinical studies of indapamide, a new 2-methylindoline antihypertensive diuretic.
Pruss, T; Wolf, PS, 1983
)
2.02
"Indapamide is a new antihypertensive diuretic agent indicated for the treatment of hypertension and edema. "( Pharmacokinetics and clinical pharmacology of indapamide.
Caruso, FS; Szabadi, RR; Vukovich, RA, 1983
)
1.97
"Indapamide was found to be an effective antihypertensive agent in a dose of 2.5 mg per day with a mean fall in blood pressure of 25/18 mmHg."( Non-invasive cardiovascular assessment of indapamide in patients with essential hypertension.
Dunn, FG; Hillis, WS; Lorimer, AR; Rae, AP; Tweddel, A, 1981
)
1.25
"Indapamide is an effective antihypertensive drug with diuretic and vasodilating activities. "( Conversion from 2.5 mg to 1.25 mg indapamide in patients with mild to moderate hypertension.
Boyd, G; Chrysant, S; Codispoti, J; Dawson, J; Gardner, T; Hill, G; Lee, W; Levine, B; Stokes, A; Vergis, J, 1995
)
2.01
"5-OH-Indapamide is a principal metabolite of indapamide, and possesses similar antihypertensive and diuretic properties. "( Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine.
Calder, JA; Schachter, M; Sever, PS, 1994
)
1.09
"Indapamide is a diuretic prescribed in the treatment of hypertension at the dosage of 2.5 mg per day. "( [Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study].
Asmar, R; Barrandon, S; Brault, Y; Bruxelles, MC; Chastang, C; de Cordoue, A; Guez, D; Malbezin, M, 1995
)
2
"Indapamide is an antihypertensive diuretic drug of which the precise antihypertensive mechanism has not been clarified. "( Indapamide treatment modifies the vascular reactivity of normotensive rat mesenteric arteries ex vivo.
Mervaala, E; Nevala, R; Paakkari, I; Tarkkila, L; Vapaatalo, H,
)
3.02
"Indapamide is a diuretic and vasodilator that does not raise blood glucose or lipid levels."( [Indapamide--a substitute diuretic for hypertensives with hyperglycemia and/or dyslipidemia].
Grossman, E; Katz, A; Nussinovitch, N; Rachima-Moaz, C; Rosenthal, T; Sharabi, Y, 1996
)
1.93
"Indapamide is a diuretic agent with direct electrophysiological effects on ionic currents involved in cardiac repolarization. "( Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol.
Drolet, B; Fiset, C; Hamelin, BA; Turgeon, J, 1997
)
2.02
"Indapamide is a nontiazidic sulfonamide diuretic which has not been previously reported as a cause of fixed drug eruption. "( Fixed drug eruption induced by indapamide. Cross-reactivity with sulfonamides.
De Barrio, M; Herrero, T; Matheu, V; Sierra, Z; Tornero, P; Zubeldia, JM,
)
1.86
"Indapamide is a thiazide-related diuretic drug with antihypertensive properties. "( Pharmacological properties of indapamide. Rationale for use in hypertension.
Bataillard, A; Sassard, J; Schiavi, P, 1999
)
2.03
"Indapamide is an oral diuretic antihypertensive drug effective for patients with mild or moderate essential hypertension."( Growth inhibitory activity of indapamide on vascular smooth muscle cells.
Del Rio, M; Ganado, P; Larcher, F; Ruiz, E; Sanz, M; Steinert, JR; Tejerina, T, 2001
)
1.32
"Indapamide is an antihypertensive drug suitable for treatment of mild hypertension in diabetics as monotherapy."( [Indapamide in the treatment of hypertension in diabetes].
Klabusay, L; Olsovský, J; Podrouzková, B, 1992
)
1.92
"Indapamide is a sulfonamide diuretic agent that has antihypertensive properties. "( Indapamide potentiates the endothelium-dependent production of cyclic guanosine monophosphate by bradykinin in the canine femoral artery.
Junquero, DC; Schini, VB; Vanhoutte, PM, 1991
)
3.17
"Indapamide is a new, nonthiazide diuretic and vasodilator."( Regression of left ventricular hypertrophy in hypertension with indapamide.
Haichin, R; Sami, M, 1991
)
1.24
"Indapamide is an effective antihypertensive agent in humans and in experimental hypertensive animals. "( Effects of indapamide on endothelium-dependent relaxations in isolated canine femoral arteries.
Dewey, J; Schini, VB; Vanhoutte, PM, 1990
)
2.11
"Indapamide is an efficient and well tolerated hypotensive agent."( [Hypotensive effectiveness and metabolic effects of indapamide in patients with primary arterial hypertension].
Niegowska, J; Sznajderman, M; Tomczak, Z,
)
1.1
"Indapamide is a nonthiazide antihypertensive agent that appears to respect the glucose tolerance in hypertensive patients."( Antihypertensive therapy in diabetic patients. The use of indapamide.
Harrower, AD; McFarlane, G, 1988
)
1.24
"Indapamide is an effective antihypertensive drug and, in contrast to thiazide diuretics, has no adverse effect on glucose tolerance in non-insulin-dependent diabetic patients."( Effect of indapamide on blood pressure and glucose tolerance in non-insulin-dependent diabetes.
Donnelly, T; Gray, CE; Harrower, AD; McFarlane, G,
)
1.26
"Indapamide is an effective antihypertensive agent for which a dual mechanism of action has been put forward: a limited diuretic activity combined with antivasoconstrictive effects, resulting in decreased peripheral vascular resistance. "( A review of 10 years of experience with indapamide as an antihypertensive agent.
Thomas, JR,
)
1.84
"Indapamide is an effective and practical treatment of hypertension of mild to moderate degree in patients with diabetes."( Indapamide in the treatment of hypertension in non-insulin-dependent diabetes.
Bevilacqua, M; Moro, B; Norbiato, G; Palumbo, P; Raggi, U,
)
2.3
"Indapamide is a methylindoline antihypertensive diuretic with a considerable peripheral vasodilatory effect."( Serum lipoprotein levels during long-term treatment of hypertension with indapamide.
Arntz, HR; Gotzen, R; Heitz, J; Meyer-Sabellek, W; Schulte, KL,
)
1.08

Effects

Indapamide SR 1.5 mg has an antihypertensive effect, maintained throughout the 24-hour administration interval. Indapamide has a dual mechanism of action: diuretic effect at the level of the distal tubule in the kidney and a direct vascular effect.

Indapamide has protecting effects in a variety of conditions associated with high cardiovascular risk, such as diabetes, left ventricular hypertrophy, nephropathy and stroke. Indapamide SR 1.5 mg has an antihypertensive effect, maintained throughout the 24-hour period.

ExcerptReferenceRelevance
"Indapamide has a dual mechanism of action: diuretic effect at the level of the distal tubule in the kidney and a direct vascular effect, both of which contribute to the antihypertensive efficacy of the drug."( An overview of the pharmacology and clinical efficacy of indapamide sustained release.
Bataillard, A; McIntyre, H; Sassard, J, 2005
)
1.3
"Indapamide has a low clearance rate and there was no evidence that the drug undergoes a first-pass effect."( Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug.
Barry, EP; Blasucci, DJ; Grebow, PE; Neiss, ES; Portelli, ST; Tantillo, NC; Treitman, JA; Vukovich, RA, 1982
)
1.25
"Indapamide SR 1.5 mg has an antihypertensive effect, maintained throughout the 24-hour administration interval, equivalent to that of immediate release indapamide 2.5 mg, but the new formulation has even less effect on circulating K+ levels."( Clinical implications of indapamide sustained release 1.5 mg in hypertension.
Donnelly, R, 1999
)
1.33
"Indapamide has a prolonged saluretic action which in combination with the direct vascular effects may well account for its antihypertensive activity."( Antihypertensive action of indapamide. Comparative studies in several experimental models.
Kyncl, J; Oheim, K; Seki, T; Solles, A, 1975
)
1.27
"Indapamide has protecting effects in a variety of conditions associated with high cardiovascular risk, such as diabetes, left ventricular hypertrophy, nephropathy and stroke."( Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.
Feihl, F; Rotaru, C; Waeber, B, 2012
)
1.48
"Indapamide has a dual mechanism of action: diuretic effect at the level of the distal tubule in the kidney and a direct vascular effect, both of which contribute to the antihypertensive efficacy of the drug."( An overview of the pharmacology and clinical efficacy of indapamide sustained release.
Bataillard, A; McIntyre, H; Sassard, J, 2005
)
1.3
"Indapamide has been the subject of a long-term safety study in which over 100 hypertensive patients have been followed up for 2 years or longer."( Multi-centre clinical investigation of indapamide in the United States: a review.
Barton, J; Bronstein, R; Caruso, F; Eff, J; Losi, M; Neiss, ES; Schotz, WE; Vukovich, RA; Webb, E; Zisblatt, M, 1983
)
1.26
"Indapamide has been successfully combined with beta-adrenergic blocking agents, methyldopa, and other anti-hypertensive agents."( Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.
Avery, GS; Brogden, RN; Chaffman, M; Heel, RC; Speight, TM, 1984
)
2.43
"Indapamide has a low clearance rate and there was no evidence that the drug undergoes a first-pass effect."( Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug.
Barry, EP; Blasucci, DJ; Grebow, PE; Neiss, ES; Portelli, ST; Tantillo, NC; Treitman, JA; Vukovich, RA, 1982
)
1.25
"Indapamide has been well tolerated by all patients."( [Ambulatory treatment of hypertension].
Henrich, H; Kababgi, MD; Schneider, KW, 1980
)
0.98
"Indapamide has been used worldwide for many years as an immediate release (IR) formulation at a dose of 2.5 mg."( Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg.
Damien, G; Huet de Barochez, B; Schiavi, P, 1999
)
1.28
"Indapamide SR 1.5 mg has an antihypertensive effect, maintained throughout the 24-hour administration interval, equivalent to that of immediate release indapamide 2.5 mg, but the new formulation has even less effect on circulating K+ levels."( Clinical implications of indapamide sustained release 1.5 mg in hypertension.
Donnelly, R, 1999
)
1.33
"Indapamide SR has also been shown to be effective (more than 20 mg enalapril) in the reduction of left ventricular mass index (LVMI) in hypertensive patients treated for one year (LIVE study)."( [Renaissance of diuretics in the treatment of hypertension].
Hörl, WH, 1999
)
1.02
"Indapamide SR 1.5 mg/day has no deleterious effect on glucose metabolism, serum levels of lipids and uric acid, or renal function. "( Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.
Weidmann, P, 2001
)
2.07
"Indapamide has antidiuretic action on central diabetes insipidus. "( [Study on the antidiuretic efficacy and mechanism of indapamide in central diabetes insipidus].
Peng, H; Wu, H; Zhao, W; Zhou, Z, 1999
)
2
"Indapamide has a prolonged saluretic action which in combination with the direct vascular effects may well account for its antihypertensive activity."( Antihypertensive action of indapamide. Comparative studies in several experimental models.
Kyncl, J; Oheim, K; Seki, T; Solles, A, 1975
)
1.27
"Indapamide has been successfully combined with beta blockers, methyldopa, and other antihypertensive agents, adding considerable effectiveness without noticeable increase in adverse reactions."( A review of 10 years of experience with indapamide as an antihypertensive agent.
Thomas, JR,
)
1.12

Actions

Indapamide can cause both severe hypokalemia and hyponatremia. Indapamide does not increase magnesium excretion when given in single doses to normal volunteers.

ExcerptReferenceRelevance
"Indapamide, because of its well-documented beneficial effects on cardiovascular and renal outcomes, represents a safe and valuable option for treating patients with high BP. "( Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.
Feihl, F; Rotaru, C; Waeber, B, 2012
)
2.2
"Indapamide does not increase magnesium excretion when given in single doses to normal volunteers."( Indapamide: a review.
Leary, WP; Reyes, AJ, 1983
)
2.43
"Indapamide can cause both severe hypokalemia and hyponatremia. "( Indapamide-induced severe hyponatremia and hypokalemia.
Chan, TY, 1995
)
3.18

Treatment

Indapamide treatment increased carotid arterial static compliance in Dahl salt-sensitive rats with a high or low NaCl diet. Treatment with indapamide SR/amlodipine was well tolerated.

ExcerptReferenceRelevance
"Indapamide treatment of 48 patients with a history of stroke prevents another stroke (NNT = 47.8 95% CI 29.6-126.6)."( [The efficacy of indapamide in different cardiovascular outcome--meta-analysis].
Brodszky, V; Farsang, C; Gulácsi, L; Kárpáti, K; Nagy, V, 2007
)
1.4
"Indapamide treatment is well tolerated."( [The efficacy of indapamide in different cardiovascular outcome--meta-analysis].
Brodszky, V; Farsang, C; Gulácsi, L; Kárpáti, K; Nagy, V, 2007
)
1.4
"Indapamide treatment partially prevented SBP increase in SHR (SHR+Indapamide: 157+/-4, SHR: 171+/-3, WKY: 119+/-3 mmHg)."( Indapamide-induced prevention of myocardial fibrosis in spontaneous hypertension rats is not nitric oxide-related.
Babál, P; Janega, P; Jendeková, L; Kojsová, S; Pechánová, O, 2007
)
2.5
"Indapamide-treated animals had significantly greater myocardial cAMP concentrations than control animals."( Effect of indapamide on cyclic adenosine 3',5'-monophosphate signal transduction system in isolated adult rat cardiomyocytes from normal myocardium and cardiac hypertrophy.
Rabkin, SW, 1993
)
1.41
"Indapamide treatment increased carotid arterial static compliance in Dahl salt-sensitive rats with a high or low NaCl diet and to a lesser extent in Dahl salt-resistant rats."( Carotid artery mechanical properties of Dahl salt-sensitive rats.
Albaladejo, P; Benetos, A; Bouaziz, H; Guez, D; Safar, ME, 1995
)
1.01
"Indapamide treatment markedly prevented BrdU incorporation (37.2+/-2.1%, 29.2+/-4.8%, 15.0+/-1.8%, 8.7+/-2.1%) indapamide 10(-6), 10(-5), 5 x 10(-5) and 5 x 10(-4) M, respectively."( Growth inhibitory activity of indapamide on vascular smooth muscle cells.
Del Rio, M; Ganado, P; Larcher, F; Ruiz, E; Sanz, M; Steinert, JR; Tejerina, T, 2001
)
1.32
"Treatment with indapamide also significantly reduced the estimated glomerular filtration rate and serum potassium and increased serum UA."( Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension.
Hanada, H; Higaki, J; Higashiura, K; Horio, T; Hosomi, N; Igase, M; Ishimitsu, T; Iwashima, Y; Kamide, K; Katabuchi, R; Kato, J; Kawano, Y; Kojima, S; Komai, N; Matsuura, H; Miki, T; Miwa, Y; Miyata, T; Morimoto, S; Nakahama, H; Nakahashi, T; Nakamura, S; Ohta, Y; Oukura, T; Rakugi, H; Sasaguri, T; Sase, K; Shimamoto, K; Shinagawa, T; Soma, M; Sugimoto, K; Takeda, K; Takiuchi, S; Tomohiro Katsuya, T; Tsuchihashi, T; Ueno, M; Yoshihara, F, 2020
)
0.9
"Treatment with indapamide SR/amlodipine was well tolerated."( Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015
)
0.98
"The treatment with indapamide SR resulted in a better or equivalent control of SBP than treatment with a standard dose of a true thiazide diuretic (hydrochlorothiazide), a calcium channel blocker (amlodipine), and an angiotensin-converting enzyme inhibitor (enalapril)."( Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure.
London, GM, 2004
)
1.02
"Treatment with indapamide was followed by a significant decrease of plasma adiponectin concentration. "( Indapamide decreases plasma adiponectin concentration in patients with essential hypertension.
Adamczak, M; Chudek, J; Piecha, G; Wiecek, A, 2007
)
2.14
"Treatment with indapamide has comparable results on both young and elderly."( Once daily indapamide in the treatment of the elderly and young hypertensive.
Glover, DR; Littler, WA; Rowlands, DB; Stallard, TJ; Young, MA, 1984
)
1
"Treatment with indapamide 1.25 mg once daily was as efficacious as the 2.5-mg once-daily dose. "( Conversion from 2.5 mg to 1.25 mg indapamide in patients with mild to moderate hypertension.
Boyd, G; Chrysant, S; Codispoti, J; Dawson, J; Gardner, T; Hill, G; Lee, W; Levine, B; Stokes, A; Vergis, J, 1995
)
0.92
"Treatment with Indapamide alone did not elicit any change in calcium accumulation in the diaphragmatic strips."( Reversal of impaired calcium homeostasis in the rat diaphragm subjected to Monocrotaline-induced pulmonary hypertension.
Al Tayeh, AU; Kanj, NA; Khoury, MY; Medawar, WA; Nassar, CF; Nasser, MG, 1999
)
0.64
"Treatment with indapamide alone at this dosage did not significantly influence most responses but in combination with perindopril it strengthened the effect of perindopril."( The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats.
Cicutti, N; Guez, D; Maurin, A; Rakusan, K; Schiavi, P, 2000
)
0.65
"Oral treatment with indapamide was found to reduce blood pressure of hypertensive rats but not of normotensive rats. "( Modification of the antihypertensive effect of indapamide by indomethacin.
Gulati, OD; Hemavathi, KG; Pasnani, JS,
)
0.71

Toxicity

Indapamide is a safe and effective agent to use in lowering the blood pressure of hypertensive patients. Adverse events and withdrawals were not significantly different between perindopril-indapamide, placebo, or routine antihypertensive drugs.

ExcerptReferenceRelevance
" The results obtained from single-blind, placebo-controlled studies indicate that indapamide is a safe and effective agent to use in lowering the blood pressure of hypertensive patients with normal renal function, those with various degrees of renal impairment, and those who are undergoing long-term maintenance hemodialysis."( Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment.
Acchiardo, SR; Skoutakis, VA, 1983
)
0.74
" Hypokalemia was the most frequently reported adverse reaction."( Clinical efficacy and safety of indapamide in the treatment of edema.
Slotkoff, L, 1983
)
0.55
" Adverse event rates (including hypokalemia) were similarly low in both groups."( Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension.
Castaigne, A; Chalmers, J; Chastang, C; Feldmann, L; Guez, D; Morgan, T, 1999
)
0.54
" Adverse events and withdrawals were not significantly different between perindopril-indapamide, placebo, or routine antihypertensive drugs."( A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.
An, N; Kang, S; Ren, M; Wu, YF, 2004
)
0.76
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43
" The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified."( Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016
)
0.43
" Both treatment regimens were well tolerated regarding adverse events or laboratory testing."( Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial.
Amodeo, C; Asmar, R; Brzozowska-Villatte, R; de Champvallins, M; Mourad, JJ, 2017
)
0.7

Pharmacokinetics

The blood levels and urinary excretion of intact indapamide were measured, and the pharmacokinetic parameters of the drug were defined. The SR formulation, by eliminating plasma peaks, allows a smoothing of the Pharmacokinetic profile ofindapamide.

ExcerptReferenceRelevance
" Other pharmacokinetic parameters are not dose related."( Pharmacokinetics and clinical pharmacology of indapamide.
Caruso, FS; Szabadi, RR; Vukovich, RA, 1983
)
0.52
" Cmax(333ng/ml) and tmax (0."( Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug.
Barry, EP; Blasucci, DJ; Grebow, PE; Neiss, ES; Portelli, ST; Tantillo, NC; Treitman, JA; Vukovich, RA, 1982
)
0.53
" The blood levels and urinary excretion of intact indapamide were measured, and the pharmacokinetic parameters of the drug were defined."( Pharmacokinetics of indapamide in dogs.
Grebow, PE; Treitman, JA, 1981
)
0.84
" The most important pharmacokinetic parameters AUC(0-infinity) and Ae were statistically compared by analysis of variance (ANOVA) and 90% confidence intervals were calculated."( Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers.
Acerbi, D; Dilger, C; Hutt, V; Pabst, G; Poli, G,
)
0.36
" The SR formulation, by eliminating plasma peaks, allows a smoothing of the pharmacokinetic profile of indapamide."( Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg.
Damien, G; Huet de Barochez, B; Schiavi, P, 1999
)
0.77
" Following a single oral administration the SR formulation had a lower dose-normalised Cmax compared to the IR formulation (17."( Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers.
Guez, D; Jochemsen, R; Schiavi, P,
)
0.37
" Blood samples for pharmacokinetic profiling were taken up to 84 h post-dose, and indapamide concentrations in plasma were determined by a validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method."( Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers.
Chu, X; Li, G; Rui, J; Tian, Y; Zhang, X; Zhang, Z, 2013
)
0.87
" The assay method shows good specificity to indapamide enantiomers, and it could be successfully applied to its pharmacokinetic studies and to therapeutic drug monitoring."( Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of indapamide enantiomers in rats.
Du, B; Jia, X; Li, H; Li, Y; Ma, S; Pang, L; Zhang, Z, 2013
)
0.87

Compound-Compound Interactions

The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug.

ExcerptReferenceRelevance
" After a 2-week single-blind placebo run-in period, patients received indapamide either alone (group I) or in combination with the previous therapy (groups II and III) for 4 months."( Clinical efficacy and quality of life with indapamide alone or in combination with beta blockers or angiotensin-converting enzyme inhibitors.
Athanassiadis, DI; Boutin, B; Cokkinos, DF; Dimopoulos, CG; Guez, D; Tourkantonis, AA; Toutouzas, PK; Tsakiris, AK, 1990
)
0.78
"A prospective evaluation was started in 1976 to study the influence of diuretics alone or combined with beta-blockers on serum lipoproteins in normal or hypertensive subjects."( Effects of indapamide and various diuretics alone or combined with beta-blockers on serum lipoproteins.
Bianchetti, MG; Mordasini, R; Weidmann, P, 1983
)
0.66
"5 mg indapamide per day, alone or in combination with other drugs."( The treatment of hypertension with indapamide alone or in combination with other drugs.
L'Homme, C; Lemieux, G, 1983
)
1.06
"5 mg/kg/day) combined with indapamide (0."( Protective effects of delapril combined with indapamide or hydrochlorothiazide in spontaneously hypertensive stroke-prone rats: a comparative dose-response analysis.
Agnati, LF; Biagini, G; Boschi, S; Torri, C; Vantaggiato, G; Zini, I; Zoli, M, 2000
)
0.86
"The efficacy of indapamide which has a thiazide-like effect on distal convoluted tubules in combination with furosemide, was evaluated in eight patients with massive edema, in regard to both Na+ excretion and diuresis."( The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema.
Fukatsu, A; Kimura, T; Muso, E; Nogaki, F; Nomura, K; Oida, E; Ono, T; Tanaka, M; Uemura, K; Yashiro, M, 2005
)
0.96
" Indapamide in combination with furosemide was well tolerated, and no significant changes in serum levels of creatinine and potassium were observed."( The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema.
Fukatsu, A; Kimura, T; Muso, E; Nogaki, F; Nomura, K; Oida, E; Ono, T; Tanaka, M; Uemura, K; Yashiro, M, 2005
)
1.53
"Thus, despite the similar BP reduction the combination of ACE-inhibitor--perindopril with indapamide retard possesses more favorable vascular and metabolic effects compared to combination with hydrochlorothiazide that potentially may account for different prognosis of patients with arterial hypertension on long-term treatment."( [Direct comparison of endothelial and metabolic effects of perindopril combination with indapamide retard or hydrochlorothiazide].
Chindareva, OI; Nechaeva, GI; Pritykina, TV; Semenkin, AA; Stroeva, TV; Zhenatov, AB; Zhivilova, LA, 2014
)
0.85
" In order to determine which combination was better as the next-step therapy for standard-dose combination of ARBs and CCBs, a combination with high-dose CCBs or a triple combination with diuretics, the authors conducted a prospective, randomized, open-label trial to determine which of the following combination is better as the next-step treatment: a combination with high-dose CCBs or a triple combination with diuretics."( Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).
Hasebe, N; Koyama, S; Maruyama, J; Morimoto, H; Nakagawa, N; Nakamura, Y; Ogawa, Y; Ohta, T; Saijo, Y; Sato, N; Takeuchi, T; Uekita, K, 2020
)
0.76
"The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs)."( Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.
Brzozowska-Villatte, R; Chalmers, J; De Champvallins, M; Mancia, G; Mourad, JJ, 2023
)
1.39
"Across medium to high cardiovascular risk population, long-term indapamide, mostly combined with perindopril-based treatment, provided evidence of benefit on mortality and morbidity."( Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.
Brzozowska-Villatte, R; Chalmers, J; De Champvallins, M; Mancia, G; Mourad, JJ, 2023
)
1.44

Bioavailability

Indapamide is well absorbed and extensively metabolized in animals and humans. Biliary excretion is the predominant route of elimination in animals. Indapamide was well absorbed in every patient (mean plasma level at the steady state was 111 +/- 41 ng/ml)

ExcerptReferenceRelevance
" Indapamide was well absorbed in every patient (mean plasma level at the steady state was 111 +/- 41 ng/ml) and its antihypertensive action was more pronounced in hypertensive than in normotensive patients."( Acute effect of indapamide on urine calcium excretion in nephrolithiasis and human essential hypertension.
Amato, F; Barbarese, F; Borghi, L; Elia, G; Melloni, E; Novarini, A; Trapassi, MR, 1988
)
1.53
" Indapamide is rapidly and well absorbed after oral ingestion, and it has a long terminal half-life in whole blood which permits once daily administration."( Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects.
Mroczek, WJ,
)
2.48
" Indapamide is well absorbed and extensively metabolized in animals and humans, with biliary excretion being the predominant route of elimination in animals."( Preclinical studies of indapamide, a new 2-methylindoline antihypertensive diuretic.
Pruss, T; Wolf, PS, 1983
)
1.49
"The study objective was to obtain detailed information on the bioavailability and pharmacokinetics of the new fixed combination of delapril and indapamide following single and multiple dosing."( Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers.
Acerbi, D; Dilger, C; Hutt, V; Pabst, G; Poli, G,
)
0.56
" The absorption rate of the SR formulation was lower and the 24 h peak-to-trough fluctuation was 4-fold lower compared to the IR formulation."( Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers.
Guez, D; Jochemsen, R; Schiavi, P,
)
0.37
" The relative bioavailability of the test tablets was 110."( Rapid and sensitive determination of indapamide in human blood by liquid chromatography with electrospray ionization mass spectrometric detection: application to a bioequivalence study.
He, Z; Li, J; Sun, J; Tang, J; Yin, J, 2005
)
0.6
" The present study suggests that the two methods based on LC-UV and LC-MS/MS were suitable for bioavailability studies of indapamide with different pharmaceutical formulations."( Comparison of liquid chromatography-ultraviolet and chromatography-tandem mass spectrometry for the determination of indapamide in human whole blood and their applications in bioequivalence studies.
Chen, H; Cui, X; Gan, F; Gu, S; Xu, R; Zhao, L, 2010
)
0.78
" The aim of this study was to estimate the influence of hypotensive drugs (angiotensine converting enzyme inhibitors (ACE-I), β-blockers, Ca-antagonists, diuretics) on the potential bioavailability of magnesium, iron, zinc and copper from buckwheat groats in vitro enzymatic digestion."( The influence of selected hypotensive drugs on the bioavailability of minerals from buckwheat groats in vitro enzymatic digestion.
Bogdański, P; Chiniewicz, B; Suliburska, J,
)
0.13
" Furthermore, the pharmacokinetics of indapamide was determined by HPLC-MS/MS to evaluate the effects of felodipine coadministered on the bioavailability of indapamide in rats in vivo."( Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats.
Di, B; He, PL; Hu, Y; Sun, G; Yan, F, 2012
)
0.88
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Indapamide, a thiazide-type diuretic, was available for many years at a dosage of 2.5 mg. The new indapamide formulation had an improved antihypertensive efficacy : safety ratio.

ExcerptRelevanceReference
" The dose-response curve of norepinephrine was not significantly affected by indapamide."( [Influence of indapamide on isolated rabbit arteries (author's transl)].
Kanda, M; Osumi, S; Seki, T; Toda, N; Usui, H, 1978
)
0.85
" The results of our clinical trial showed that metipamide is an effective first-line antihypertensive agent, in that it combines satisfactory reduction of blood pressure with a low frequency of side-effects and a simple once-daily dosage regime."( Therapeutic monitoring of metipamide during antihypertensive therapy.
Grafnetterová, J; Klíma, J; Kubelka, Z, 1989
)
0.28
" A fixed once-daily dosage of an antihypertensive agent may, however, increase patient compliance and convenience."( Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril.
Lacourciere, Y, 1988
)
0.5
" After a wash-out period of 1 week, captopril was given initially as 75 mg/day for 2 weeks; at the end of this period, the dosage was doubled to 150 mg/day and continued at this level for a further 2 weeks."( Antihypertensive effect of indapamide given in conjunction with captopril in severe hypertension.
Dimkovic, S; Kocijancic, M, 1986
)
0.57
" The elderly patients were found to benefit from the simple dosage and the lack of side effects such as postural hypotension."( The antihypertensive action of indapamide: results of a French multicentre study of 2,184 ambulant patients.
Coppolani, T; Mimran, A; Zambrowski, JJ, 1981
)
0.55
" At all dosage levels, indapamide produced markedly greater therapeutic success rates than did the placebo."( Multicenter dose-response study of the effect of indapamide in the treatment of patients with mild to moderate hypertension.
Bolton, S; Capone, P; Neiss, ES; Reeves, RL; Vukovich, RA, 1983
)
0.83
" It is concluded that indapamide and pindolol at the dosage levels used are drugs of comparable antihypertensive activity."( Indapamide versus beta-blocker therapy: a double-blind, crossover study in essential hypertension.
Jurisic, M; Rumboldt, M; Rumboldt, Z, 1984
)
2.02
" Preincubation with IN or C did not affect the dose-response curve of NA-induced contractions."( A comparative study on possible calcium antagonistic properties of indapamide and other drugs potentially interfering with calcium transport in isolated vascular smooth muscle.
De Wildt, DJ; Hillen, FC, 1984
)
0.5
" There were no significant differences among the three dosage levels of indapamide."( Indapamide, a new antihypertensive/diuretic agent, in the treatment of patients with edema.
Bratnick, J; Eff, J; Neiss, E; Vukovich, RA; Zisblatt, M, 1984
)
1.94
" It is therefore concluded that continuous control of water intake and analysis of the stability of the drug is essential for the establishment of proper dose-response relationships."( Drinking water and drug dosage in rat studies.
Jakobsen, P; Jespersen, LT; Mikkelsen, EO; Pedersen, OL, 1983
)
0.27
" There is growing experimental and clinical evidence that indapamide, an antihypertensive agent with only limited diuretic activity at low dosage (2."( The place of indapamide in the treatment of arterial hypertension.
Thénot, A, 1983
)
0.88
" All groups had mean diastolic pressure controlled at or below the 90 mmHg criterion during the period of constant methyldopa dosage for those patients who required Step 2 therapy."( Indapamide in the stepped-care treatment of obese hypertensive patients.
Godfrey, JC; Neiss, ES; Noble, RE; Vukovich, RA; Webb, EL; Zisblatt, M, 1983
)
1.71
" Coadministration of acetazolamide with 14C-labeled indapamide to rats, resulted in a 5-fold drop in the blood levels of total radioactivity, relative to rats dosed with [14C]indapamide alone."( Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C]Indapamide in the rat.
Lettieri, JT; Portelli, ST, 1983
)
0.73
" Dose-response relationships to these pressor agents were shifted in parallel to the right after treatment."( Extrarenal contributions to indapamide's antihypertensive mechanism of action.
Giles, T; McMahon, FG; Noveck, RJ; Quiros, A, 1983
)
0.56
" In 5 others, dosage had to be maintained at 1 tablet daily."( Indapamide in the treatment of essential arterial hypertension in the elderly.
Brems, H; Thomas, J; Van Hee, W, 1981
)
1.71
"In an open study 30 hypertensive outpatients have been treated with Indapamide in a dosage of 2,5 mg daily in the morning for eight weeks."( [Ambulatory treatment of hypertension].
Henrich, H; Kababgi, MD; Schneider, KW, 1980
)
0.5
" In addition, in the experimental groups dose-response curves to NE (10(-8) to 10(-4) M) and to KCI (20-120 mM) were shifted upward and to the left with respect to the control hypercholesterolemic group."( Effects of indapamide on vascular reactivity in hypercholesterolemic rabbits.
Chulia, T; Del Rio, M; Tejerina, T, 1993
)
0.68
" The daily dosage of enalapril was increased, if required, from 10 to 20 to 40 mg and that of nifedipine from 40 to 60 to 80 mg at 4-week intervals during the 12-week titration period."( Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995
)
0.29
" Hydrochlorothiazide (10 microM) and cicletanine (10 microM) were weak calcium antagonists shifting the calcium dose-response curve half a log unit to the right."( Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds.
Calder, JA; Schachter, M; Sever, PS, 1993
)
0.29
" Following single and on the last day of the multiple dosing regimen, blood samples were withdrawn and serum concentrations of delapril and its metabolites M1, M2 and M3 and whole blood concentrations of indapamide were quantified by means of HPLC methods."( Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers.
Acerbi, D; Dilger, C; Hutt, V; Pabst, G; Poli, G,
)
0.55
" Dose-response (10(-7)-10(-4) M) effects of indapamide or chlorthalidone on reperfusion-induced arrhythmias, coronary flow, and heart rate (HR) were evaluated in a randomized blinded fashion."( Influence of indapamide and chlorthalidone on reperfusion-induced ventricular fibrillation in isolated guinea pig hearts.
Fiset, C; Kingma, JG; Kingma, ML; Lacoursière, L; Turgeon, J, 1995
)
0.92
"Thiazide diuretics in high dosage adversely affect the lipid profile."( A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides.
Ames, RP, 1996
)
0.51
"5) of indapamide, a diuretic related to thiazide, has been pointed out by using conventional sphygmomanometric measurement 24 h after dosing in clinic, in two large European randomized, double-blind, controlled studies (2 and 3 months)."( Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies.
Asmar, R; Boutelant, S; Guez, D; Mallion, JM, 1998
)
1.04
"5 mg dosage of the new indapamide formulation had an improved antihypertensive efficacy : safety ratio."( Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group.
Ambrosioni, E; de Cordoüe, A; Degaute, JP; Guez, D; MacMahon, M; Malin, PL; Pujol, DR; Safar, M, 1998
)
0.85
" Dose-response curves were repeated after local tetraethylammonium (TEA) administration to determine the role of potassium channel activation and, in patients with the Gitelman syndrome, to determine the role of the thiazide-sensitive Na-Cl cotransporter in the vasodilator effect of hydrochlorothiazide."( Thiazide-induced vasodilation in humans is mediated by potassium channel activation.
Hughes, AD; Pickkers, P; Russel, FG; Smits, P; Thien, T, 1998
)
0.3
" After optimisation, the chosen ratio of these 2 constituents allowed the release of more than 70% of the dosage over 16 hours in a very reproducible manner."( Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg.
Damien, G; Huet de Barochez, B; Schiavi, P, 1999
)
0.56
" The recently developed sustained release (SR) formulation of indapamide allows use of a lower daily dosage of the drug, thereby improving its efficacy:safety ratio in comparison with immediate release formulations."( Concluding remarks. Pursuit of the optimal outcome in hypertension.
Hansson, L, 1999
)
0.54
" This trial was a multinational randomized double-blind study with doubling of active drug dosage in nonresponders."( Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension.
Castaigne, A; Chalmers, J; Chastang, C; Feldmann, L; Guez, D; Morgan, T, 1999
)
0.54
" Treatment with indapamide alone at this dosage did not significantly influence most responses but in combination with perindopril it strengthened the effect of perindopril."( The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats.
Cicutti, N; Guez, D; Maurin, A; Rakusan, K; Schiavi, P, 2000
)
0.65
"There was a linear dose-response relationship (P<0."( Fixed low-dose combination therapy in hypertension--a dose response study of perindopril and indapamide.
Asmar, R; Leenen, FH; Myers, MG; Safar, M, 2000
)
0.53
" Urine was collected over the dosing interval (24 h)."( Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers.
Guez, D; Jochemsen, R; Schiavi, P,
)
0.37
" There were no unexpected adverse events or side-effect trends and no dose-response or clinically significant laboratory, ECG, or physical examination adverse effects."( Ambulatory blood pressure profiles in patients treated with once-daily diltiazem extended-release or indapamide alone or in combination.
Prisant, LM, 2000
)
0.52
"A new sensitive, simple, rapid and precise reversed-phase high performance liquid chromatographic (HPLC) and two spectrophotometric methods have been developed for resolving binary mixture of perindopril and indapamide in the pharmaceutical dosage forms."( Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations.
Erk, N, 2001
)
0.72
" Studies comparing this dosage of perindopril/ indapamide with other combination therapies would be beneficial in allowing the place of perindopril/indapamide to be more accurately determined."( Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.
Cheer, SM; Goa, KL; Matheson, AJ, 2001
)
0.95
"Simple, fast and reliable derivative spectrophotometric methods were developed for determination of indapamide in bulk and pharmaceutical dosage forms."( Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms.
Altínöz, S; Süslü, I, 2002
)
0.78
"24 mg/kg/day) or each component given alone at the same dosage for 3 and 28 days."( Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs.
Clergue, M; Duriez, M; Kamsu-Kom, N; Lévy, BI; Silvestre, JS, 2002
)
0.53
" Diuretics used at lower dosage than in the past are effective in reducing morbidity and mortality and continue to be drugs of first choice in the treatment of hypertension."( Clinical role of Natrilix SR in the treatment of at-risk hypertensive patients.
Ambrosioni, E; Veronesi, M, 2003
)
0.32
" Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol."( Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Asmar, R; Battegay, E; Chamontin, B; De Leeuw, PW; Duprez, D; Hitzenberger, G; Mallion, JM; O'Brien, E; O'Rourke, MF; Rahn, KH; Romero, R; Safar, ME, 2004
)
0.55
" The trials selected were published between 1973 and 2004, evaluated monotherapy with trial drugs as fixed-dosage or with dosage increase, and assessed blood pressure reduction between 2 and 3 months."( A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.
Auquier, P; Baguet, JP; Boyer, L; Debensason, D; Robitail, S, 2005
)
0.33
"Multivariate experimental design has been used to optimize 2 flow-injection spectrophotometric methods for the determination of indapamide in pharmaceutical dosage forms, both pure and commercial tablets."( Optimization of two flow-injection spectrophotometric methods for the determination of indapamide in pharmaceutical dosage forms.
Barciela, J; García, S; Herrero, C; Peña, RM; Rodríguez, JC,
)
0.56
"In this 1-year multicentre randomized double-blind study, patients received an increasing dosage of perindopril/indapamide (n = 284) or enalapril (n = 272)."( Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.
Dahlöf, B; De Leeuw, PW; de Simone, G; Degaute, JP; Dubourg, O; García-Puig, J; Gosse, P; Guéret, P; Karpov, Y; Magometschnigg, D; Matos, L; Schmieder, R, 2005
)
0.92
" Once daily dosing of the preparation provided high level of compliance of patients with treatment."( [Effect of twelve-month combined therapy with perindopril and indapamide on the level of blood pressure and left ventricular hypertrophy in patients with hypertensive disease].
Alekhin, MN; Chumakova, OS; Larina, VN; Sidorenko, BA; Timofeeva, LA; Ugriumov, MO, 2006
)
0.57
" The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance."( Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse, P, 2006
)
0.71
"25 mg with decreases in mean 24-h ambulatory BP from 24 to 48 h and 48 to 72 h after dosing being -11."( The impact of one or two missed doses on the duration of action of combined perindopril and indapamide.
Leenen, FH; Myers, MG, 2007
)
0.56
"625 mg with reductions in mean 24-h blood pressure from 24-48 h and 48-72 h after dosing being -11."( Persistence of the antihypertensive effect of low-dose combination therapy in mild hypertension.
Leenen, FH; Myers, MG, 2006
)
0.33
" After a 4-week placebo period, 94 and 107 patients with uncomplicated hypertension were randomly assigned to treatment with atenolol (AT) at dosage of 50 mg per day or perindopril/indapamide (PER/IND) at dosage of 2/0."( Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs.
Dolan, E; Jin, Y; Li, Y; O'Brien, E; Protogerou, A; Richart, T; Safar, ME; Staessen, JA; Thijs, L; Wang, JG, 2011
)
0.56
" Dosage could be increased to 10/2."( Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
Pella, D, 2011
)
0.59
"Owing to the low effective dosage of indapamide (1."( Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: a pilot study.
Alonso, D; Grases, F; Pieras, E; Pizá, P; Prieto, RM, 2012
)
0.94
"The objective of this study was to develop and validate the in vitro-in vivo correlations (IVIVCs) of three commercially available immediate-release solid dosage forms of indapamide using drug dissolution/absorption simulating system (DDASS)."( In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
He, X; Li, Z; Liu, W; Ma, Y; Shi, X; Xun, M; Yaro, P, 2014
)
0.82
" Perindopril/indapamide dosage could be increased, from 5/1."( Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.
Gorbat, TV; Netchessova, TA; Shepelkevich, AP, 2014
)
1.05
"Determination of the effectiveness and safety of different dosing regimens during the day (in the morning or at bedtime) combination therapy including azilsartan medoxomil in patients with essential hypertension and metabolic syndrome (MS)."( [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
Fendrikova, AV; Sirotenko, DV; Skibitskiy, AV; Skibitskiy, VV, 2016
)
0.43
"When combined with essential hypertension and MS azilsartana use of combination drug therapy provided achievement of the target values of blood pressure in the majority of patients, a significant improvement in the main indicators of ABPM, CAP, and the rigidity of the vascular wall, as well as the normalization of daily profile of blood pressure in the majority of patients, regardless of dosing regimen during the day."( [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
Fendrikova, AV; Sirotenko, DV; Skibitskiy, AV; Skibitskiy, VV, 2016
)
0.43
" The primary objective of the PETRA study was to evaluate the efficacy of blood pressure (BP) control with once daily administration of the different dosage strengths of the once-daily, triple fixed combination of perindopril, indapamide, and amlodipine."( The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study.
Ábrahám, G; Dézsi, CA, 2017
)
0.87
"Combined dissolution and permeation systems are designed to simultaneously assess the dissolution of a pharmaceutical dosage form and the permeation of dissolved drugs therefrom."( Simultaneous Evaluation of Dissolution and Permeation of Oral Drug Solid Formulations for Predicting Absorption Rate-Limiting Factors and In Vitro-In Vivo Correlations: Case Study Using a Poorly Soluble Weakly Basic Drug.
Feng, G; He, X; Huang, C; Li, Z; Tian, S; Wang, Y; Wu, Z; Xun, M, 2019
)
0.51
" These findings may apply to drugs administered as a single dosage form or in separate dosage forms and hence need to be well controlled to assure effective treatments and patient safety."( Insights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs.
Alhalaweh, A; Bergström, CAS; El Sayed, M, 2020
)
0.56
"Comparative study of different spectrophotometric approaches used for the simultaneous determination of perindopril, indapamide, and amlodipine in bulk powder and in dosage form Triplixam."( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data.
Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023
)
1.12
"The methods were applied for the analysis of the mixture in the pharmaceutical dosage form Triplixam and in vitro release at intestinal pH (7."( In Vitro Dissolution Profile of Antihypertensive Mixture: Comparison Between Multivariate Methods and Statistical and Graphical Representation of Different Univariate Spectrophotometric Data.
Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
indolesAny compound containing an indole skeleton.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Indapamide Action Pathway319

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.12090.003245.467312,589.2998AID2517
endonuclease IVEscherichia coliPotency0.02510.707912.432431.6228AID2565
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.11880.006038.004119,952.5996AID1159521
GALC proteinHomo sapiens (human)Potency0.631028.183828.183828.1838AID1159614
Smad3Homo sapiens (human)Potency0.31620.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency32.46480.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency28.06410.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.33740.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency20.03850.005428.02631,258.9301AID1346982
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720580
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.87510.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.37620.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency21.87510.143427.612159.8106AID1159516
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency6.30960.036619.637650.1187AID2100
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency56.23413.548119.542744.6684AID743266
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency35.48130.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency1.17940.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency4.46680.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency0.89130.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Carbonic anhydrase 12Homo sapiens (human)Ki3,040.46850.00021.10439.9000AID1798598; AID1803141; AID367617
Bile salt export pumpHomo sapiens (human)IC50 (µMol)137.56670.11007.190310.0000AID1443980; AID1449628; AID1473738
Carbonic anhydrase 1Homo sapiens (human)Ki3,046.23400.00001.372610.0000AID1798598; AID1803141; AID367608
Carbonic anhydrase 2Homo sapiens (human)Ki3,040.74730.00000.72369.9200AID1798598; AID1803141; AID367609
Carbonic anhydrase 3Homo sapiens (human)Ki51.60090.00022.010210.0000AID1798598; AID367610
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)2.91800.11003.26419.0330AID625146
Carbonic anhydrase 4Homo sapiens (human)Ki18.77420.00021.97209.9200AID1798598; AID367611
Carbonic anhydrase 6Homo sapiens (human)Ki18.97320.00011.47109.9200AID1798598; AID367614
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki18.87090.00001.27259.9000AID1798598; AID367612
Carbonic anhydrase 7Homo sapiens (human)Ki17.49420.00021.37379.9000AID1060765; AID1798598; AID367615
Carbonic anhydrase 9Homo sapiens (human)Ki3,040.47130.00010.78749.9000AID1798598; AID1803141; AID367616
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Carbonic anhydrase 13Mus musculus (house mouse)Ki18.74560.00021.39749.9000AID1798598; AID367618
Carbonic anhydrase 14Homo sapiens (human)Ki19.45090.00021.50999.9000AID1798598; AID367619
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki18.78290.00001.34129.9700AID1798598; AID367613
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Kd1.93900.00070.29432.0000AID1373173; AID1373185; AID1803392; AID780926
Carbonic anhydrase 1Homo sapiens (human)Kd5.59570.00071.368910.0000AID1373164; AID1373176; AID1803392; AID527831; AID780930
Carbonic anhydrase 2Homo sapiens (human)Kd1.34340.00000.41575.5500AID1373165; AID1373177; AID1803392; AID527832; AID527836; AID780929
Carbonic anhydrase 3Homo sapiens (human)Kd14.05250.00841.18044.6000AID1373166; AID1373178
Carbonic anhydrase 4Homo sapiens (human)Kd0.03870.00030.30841.5000AID1373167; AID1373179
Carbonic anhydrase 6Homo sapiens (human)Kd0.32030.00100.71724.0000AID1373170; AID1373182; AID780928
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kd0.33850.00700.38641.0000AID1373168; AID1373180
Carbonic anhydrase 7Homo sapiens (human)Kd1.47510.00010.37616.6700AID1373171; AID1373183; AID1803392; AID527833; AID527837; AID780927
Carbonic anhydrase 9Homo sapiens (human)Kd0.21600.00060.13420.6700AID1373172; AID1373184
Carbonic anhydrase 13Homo sapiens (human)Kd1.27940.00070.384910.0000AID1373174; AID1373186; AID1803392; AID527834; AID527838; AID780925
Carbonic anhydrase 14Homo sapiens (human)Kd0.03170.00040.09510.4420AID1373175; AID1373187
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kd0.02970.00050.53992.5000AID1373169; AID1373181
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Kinact0.01000.00300.66749.6000AID328983; AID411536
Carbonic anhydrase 1Homo sapiens (human)Kinact51.90000.01000.93878.6000AID328974; AID411527
Carbonic anhydrase 2Homo sapiens (human)Kinact2.52000.00300.794610.0000AID328975; AID411528
Carbonic anhydrase 4Homo sapiens (human)Kinact0.21300.07402.39348.5900AID328977; AID411530
Carbonic anhydrase 6Homo sapiens (human)Kinact1.60600.00090.72615.3000AID328980; AID411533
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kinact0.89000.02000.85809.4000AID328978; AID411531
Carbonic anhydrase 7Homo sapiens (human)Kinact0.00020.00020.28525.7300AID328981; AID411534
Carbonic anhydrase 9Homo sapiens (human)Kinact0.03600.00500.31976.6700AID328982; AID411535
Carbonic anhydrase 13Mus musculus (house mouse)Kinact0.01300.01300.56698.2300AID328984; AID411537
Carbonic anhydrase 14Homo sapiens (human)Kinact4.95000.00021.44958.5900AID328985; AID411538
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kinact0.27400.00900.92319.0400AID328979; AID411532
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (242)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID328982Inhibition of human catalytic domain carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328981Inhibition of human full length carbonic anhydrase 72008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1373183Binding affinity to recombinant human N-terminal His-tagged carbonic anhydrase 7 (3 to 264 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID197021Total volume of urine excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-1) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID411529Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411529Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID230883Ratio of amount of Na+ excreted to amount of K+ excreted in urine of rat of protocol A-1 test1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID1373175Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 14 (20 to 280 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID328974Inhibition of human full length carbonic anhydrase 12008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID367608Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367608Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328979Inhibition of human full length carbonic anhydrase 5B2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID367611Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367611Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID197024Total volume of urine excreted during 4 hr after oral administration of 5 mg/kg of the test agent (protocol B) on 5 male and female rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1373164Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 1 (3 to 261 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID411536Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411536Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411534Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411534Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID328983Inhibition of human catalytic domain carbonic anhydrase 122008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID411535Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411535Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID527834Binding affinity to human recombinant carbonic anhydrase 13 by thermal shift assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1373187Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 14 (20 to 280 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID197032Amount of sodium ions excreted during 4 hr after oral administration of 5 mg/kg of the test agent (protocol B) on 5 male and female rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID197023Total volume of urine excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-2) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1373166Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 3 (4 to 260 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID328984Inhibition of mouse full length carbonic anhydrase 132008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID527836Binding affinity to human recombinant carbonic anhydrase 2 by isothermal titration calorimetry assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1373180Binding affinity to recombinant human full length N-terminal His6-tagged mitochondrial carbonic anhydrase 5A expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1373171Binding affinity to recombinant human N-terminal His-tagged carbonic anhydrase 7 (3 to 264 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID197031Amount of sodium ions excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-2) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328976Inhibition of human full length carbonic anhydrase 32008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID367612Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367612Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1373176Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 1 (3 to 261 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1373174Binding affinity to recombinant human full length N-terminal His-tagged carbonic anhydrase 13 (1 to 262 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID411527Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411527Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328980Inhibition of human full length carbonic anhydrase 62008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197028Amount of potassium ions excreted during 4 hr after oral administration of 5 mg/kg of the test agent (protocol B) on 5 male and female rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID411531Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411531Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID780926Binding affinity to human recombinant carbonic anhydrase 12 by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID197025Amount of potassium ions excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-1) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1373168Binding affinity to recombinant human full length N-terminal His6-tagged mitochondrial carbonic anhydrase 5A expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1373177Binding affinity to recombinant human full length N-terminal His-tagged carbonic anhydrase 2 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1373182Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 6 expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID230884Ratio of amount of Na+ excreted to amount of K+ excreted in urine of rat of protocol A-2 test1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID780930Binding affinity to human recombinant carbonic anhydrase 1 expressed in Escherichia coli BL21 (DE3) by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID527837Binding affinity to human recombinant carbonic anhydrase 7 by isothermal titration calorimetry assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID1373181Binding affinity to recombinant human full length N-terminal His6-tagged mitochondrial carbonic anhydrase 5B (40 to 317 residues) expressed in Escherichia coli Rosetta 2 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent t2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID780927Binding affinity to human recombinant carbonic anhydrase 7 by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID1373186Binding affinity to recombinant human full length N-terminal His-tagged carbonic anhydrase 13 (1 to 262 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID367616Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367616Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID328975Inhibition of human full length carbonic anhydrase 22008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1373188Acid ionization constant, pKa of sulfonamide group of the compound by NMR chemical shift based method2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID367614Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367614Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1373179Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 4 expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID527838Binding affinity to human recombinant carbonic anhydrase 13 by isothermal titration calorimetry assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID197029Amount of sodium ions excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-1) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID328985Inhibition of human full length carbonic anhydrase 142008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID411530Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411530Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID527832Binding affinity to human recombinant carbonic anhydrase 2 by thermal shift assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID411533Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411533Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1373184Binding affinity to recombinant human carbonic anhydrase 9 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID780928Binding affinity to human recombinant carbonic anhydrase 6 expressed in Escherichia coli Rosetta2 (DE3) by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID367610Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367610Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328978Inhibition of human full length carbonic anhydrase 5A2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID527833Binding affinity to human recombinant carbonic anhydrase 7 by thermal shift assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID1373185Binding affinity to recombinant human carbonic anhydrase 12 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID328977Inhibition of human full length carbonic anhydrase 42008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID527831Binding affinity to human recombinant carbonic anhydrase 1 by thermal shift assay2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1373178Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 3 (4 to 260 residues) expressed in Escherichia coli BL21 (DE3) assessed as intrinsic dissociation constant in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1373172Binding affinity to recombinant human carbonic anhydrase 9 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1373173Binding affinity to recombinant human carbonic anhydrase 12 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1373165Binding affinity to recombinant human full length N-terminal His-tagged carbonic anhydrase 2 (1 to 260 residues) expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID411528Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411528Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411537Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411537Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID230885Ratio of amount of Na+ excreted to amount of K+ excreted in urine of water-loaded rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID411538Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411538Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID197027Amount of potassium ions excreted during 18 hours after single administration of 5 mg/kg of the test agent (protocol A-2) on 6 rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines.
AID1373170Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 6 expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID367613Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367613Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1060765Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.
AID780925Binding affinity to human recombinant carbonic anhydrase 13 by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID367619Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367619Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367617Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367617Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID780929Binding affinity to human recombinant carbonic anhydrase 2 by thermal shift assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Benzenesulfonamides with pyrimidine moiety as inhibitors of human carbonic anhydrases I, II, VI, VII, XII, and XIII.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID411532Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411532Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1373169Binding affinity to recombinant human full length N-terminal His6-tagged mitochondrial carbonic anhydrase 5B (40 to 317 residues) expressed in Escherichia coli Rosetta 2 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID367618Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367618Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1373167Binding affinity to recombinant human N-terminal His6-tagged carbonic anhydrase 4 expressed in Escherichia coli BL21 (DE3) in presence of ANS by fluorescent thermal shift assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID367615Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367615Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID367609Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367609Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1803141CA Inhibition Assay from Article 10.3109/14756366.2011.638921: \\Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.
AID1798598CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1803392Thermal Shift Assay (TSA) from Article 10.3109/14756366.2012.757223: \\Benzenesulfonamides with benzimidazole moieties as inhibitors of carbonic anhydrases I, II, VII, XII and XIII.\\2014Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 29, Issue:1
Benzenesulfonamides with benzimidazole moieties as inhibitors of carbonic anhydrases I, II, VII, XII and XIII.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,016)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990229 (22.54)18.7374
1990's163 (16.04)18.2507
2000's330 (32.48)29.6817
2010's233 (22.93)24.3611
2020's61 (6.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.09 (24.57)
Research Supply Index7.27 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index188.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (102.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials350 (32.14%)5.53%
Reviews104 (9.55%)6.00%
Case Studies60 (5.51%)4.05%
Observational15 (1.38%)0.25%
Other560 (51.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (37)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Double-dummy, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension [NCT03814148]Phase 30 participants (Actual)Interventional2019-06-30Withdrawn(stopped due to The design of this protocol was rewritten due to regulatory recommendations.)
Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension [NCT03747978]Phase 430 participants (Actual)Interventional2016-10-01Completed
Evaluation of spironolactoNe Versus Indapamide on Target Organ Damage in Patients With Obesity and hYpertension(ENVOY) [NCT03626506]400 participants (Anticipated)Interventional2019-02-13Recruiting
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication [NCT05103332]Phase 2672 participants (Actual)Interventional2021-11-05Active, not recruiting
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study [NCT03785067]Phase 31 participants (Actual)Interventional2020-02-27Terminated(stopped due to Contractual and financial issues.)
"Multinational Observational Uncontrolled Open Programme The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy" [NCT03722524]1,247 participants (Actual)Observational2018-10-01Completed
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) MRI Sub-study [NCT03783754]4 participants (Actual)Interventional2018-08-09Terminated(stopped due to Not feasible to continue)
The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure [NCT04455178]Phase 4200 participants (Anticipated)Interventional2020-09-23Recruiting
A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension [NCT01172431]Phase 4240 participants (Actual)Interventional2010-09-30Completed
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Adequately Responded by Fimasartan 30 mg [NCT05878561]Phase 3244 participants (Anticipated)Interventional2022-11-09Recruiting
"An Open-label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between BR1015-1 and BR1015-2 in Healthy Volunteers." [NCT05097794]Phase 131 participants (Actual)Interventional2021-08-16Completed
A Randomized, Double-blind, Active-controlled, 2-parallel Group, Optional Titration, Multicenter, Phase 3b Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without Diuretics Combination in Elderly Patients Wi [NCT03246555]Phase 3241 participants (Actual)Interventional2016-07-15Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension [NCT02655029]2,285 participants (Actual)Observational [Patient Registry]2015-11-25Completed
A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate Hypertension and Type 2 Diabetes Mellitus [NCT00980187]Phase 456 participants (Actual)Interventional2008-03-31Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation [NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS [NCT04686643]Phase 3306 participants (Anticipated)Interventional2021-02-01Not yet recruiting
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension [NCT04518293]Phase 31,385 participants (Actual)Interventional2021-06-26Completed
The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension [NCT01996085]144 participants (Actual)Interventional2013-01-31Completed
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril Erbumine/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg Tablets (Pharmtechnology LLC, Republic of Belarus) and Triplixam® 10 mg/2.5 mg/10 mg Tablets (L [NCT05940909]Phase 150 participants (Anticipated)Interventional2023-06-24Recruiting
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Substudies: MRI, Cognitive [NCT02699645]Phase 31,500 participants (Anticipated)Interventional2017-09-28Recruiting
Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial) [NCT02710552]Phase 4100 participants (Anticipated)Interventional2016-04-30Not yet recruiting
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India [NCT05683301]Phase 41,968 participants (Anticipated)Interventional2022-08-30Recruiting
Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial) [NCT02710539]Phase 4100 participants (Anticipated)Interventional2016-04-30Not yet recruiting
"Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Test Product PERINDOPRES® TRIO, 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide/ 10 mg Amlodipine Tablets (PrJSC Pharmaceutical Firm [NCT05470764]Phase 152 participants (Actual)Interventional2021-05-30Completed
Randomized, Double-blind, Triple-dummy, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Leningrado Association in the Treatment of Hypertension [NCT03814109]Phase 30 participants (Actual)Interventional2022-04-30Withdrawn(stopped due to Sponsor decision)
The Hypertension in the Very Elderly Trial (HYVET) [NCT00122811]Phase 44,000 participants (Anticipated)Interventional2000-11-30Active, not recruiting
Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS) [NCT05013463]Phase 235 participants (Anticipated)Interventional2021-10-01Recruiting
IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs [NCT00128518]Phase 4139 participants (Actual)Interventional2004-10-31Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]Phase 43,344 participants (Actual)Interventional2000-03-31Completed
Study on the Effect of Genetic Polymorphisms of Uridine Diphosphate Glucuronosyl Transferase (UGT) on the Pharmacokinetics of Indapamide in Egyptians [NCT05294484]Phase 438 participants (Anticipated)Interventional2022-03-15Not yet recruiting
Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. [NCT05110898]Phase 3400 participants (Anticipated)Interventional2022-08-01Not yet recruiting
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension [NCT04518306]Phase 3295 participants (Actual)Interventional2021-06-06Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Randomized, Phase 3, Multicenter, Open Label, Evaluating the Effect of the Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With Hyzaar® in the Treatment of Hypertension [NCT01620788]Phase 3636 participants (Anticipated)Interventional2019-11-27Suspended(stopped due to Substancial amendment)
"Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover, Comparative, Oral Bioequivalence Study of Test Product PERINDOPRES® DUO, 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide Tablets (PrJSC Pharmaceutical Firm Darnitsa) and Refer [NCT05464745]Phase 142 participants (Actual)Interventional2021-05-19Completed
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention [NCT06111885]Phase 299 participants (Anticipated)Interventional2024-04-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03722524 (5) [back to overview]Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline
NCT03722524 (5) [back to overview]The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline

Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline

The assessment of the target office BP levels (SBP <140 mm Hg and DBP <90 mm Hg) was performed in accordance with ESC Guidelines for the management of arterial hypertension (2013) (NCT03722524)
Timeframe: Baseline, 3 months

Interventionpercentage of patients (Number)
Patients With Arterial Hypertension93.38

[back to top]

The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.

Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension14.34

[back to top]

The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the SF-36 survey Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension23.57

[back to top]

The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline

"Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.~The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT03722524)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Patients With Arterial Hypertension13.64

[back to top]

The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline

Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded. (NCT03722524)
Timeframe: Baseline, 3 months

Interventionmm Hg (Mean)
Patients With Arterial Hypertension33.47

[back to top]